BioMark offers a robust diagnostic oncology platform for early diagnosis of cancer, faster monitoring treatment response and better monitoring for recurrence. The company has completed phase lll clinical trials on Amantadine assay platform for pre screening cancerapplication. A large trial with IUCPQ to complete the development comprehensive early lung cancer detection liquid biopsy metabolomic based assay is planned. The company plans to establish a certified lab in Quebec city to offer tests